Rosalyn W Sayaman

8PUBLICATIONS
78CO-AUTHORS
Predictive and prognostic markersTumour immunologyLiquid biopsiesEpigenetics (incl. genome methylation and epigenomics)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 23, 2025
YAP1 Dysfunction Promotes Molecular Properties Linked to Breast Cancer Susceptibility.

Tara Fresques, Jennifer C Lopez, Deborah Hussey

|Dec 09, 2025
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.

Mark Jesus M Magbanua, Nayelis A Manon, Denise M Wolf

|Jun 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.

Denise M Wolf, Christina Yau, Michael Campbell

|Nov 15, 2024
Luminal epithelial cells integrate variable responses to aging into stereotypical changes that underlie breast cancer susceptibility.

Rosalyn W Sayaman, Masaru Miyano, Eric G Carlson

|Oct 10, 2024
Super-enhancer profiling reveals ThPOK/ZBTB7B, a CD4 + cell lineage commitment factor, as a master regulator that restricts breast cancer cells to a luminal non-migratory phenotype.

Camila D Arcuschin, Kamin Kahrizi, Rosalyn W Sayaman

|Mar 12, 2024
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.

Mark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman

Pageof 2

Frequent Collaborators

4 joint publications

Laura van 't Veer

3 joint publications

Christina Yau

3 joint publications

Mark A LaBarge

3 joint publications

Angela M DeMichele